Collector
Giriş Yap
GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent | Collector
GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent

GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent

Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed fir...

Go to News Site